The drug is a modified form of beta-glucocerebrosidase, obtained recombinantly. Imiglucerase replaces the deficiency of this enzyme, relieves initial pathophysiological changes and prevents the development of secondary pathological manifestations of the disease.
Glurazyme® treatment reduces size of spleen and liver, improves or normalizes blood platelet counts and mineral bone density, reduces bone-marrow infiltration and also weakens pain in the bones.
Glurazyme (imiglucerase) is indicated for use as long-term enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant non-neurological manifestations of the disease
Glurazyme is indicated for use in adult and pediatric patients: for long-term enzyme replacement therapy for patients with a confirmed diagnosis of Gaucher disease type 1 (without neuronopathic manifestations) and type 3 (with chronic neuronopathic manifestations), who have clinically significant manifestations of Gaucher disease, having one or more of the following symptoms:
- Bone diseases
- Hepatomegaly and splenomegaly
GENERIUM is the only company in Russia that carried out the development and production of Imiglucerase biosimilar.
ЛП-005297 от 17.01.2019